Sungjin Ju, Jang Hyeon Lee, Jiyun Yang, Tae Yeong Jeong, Chang Geun Choi, Yerim Lee, Seongkwang Cha, Jeongeun Park, S. Kim, Sanghun Kim, Jeaseok Seong, Hyunji Lee, Kyoungmi Kim
2026.6.1Molecular Therapy Nucleic Acids
Abstract
safety profile, characterized by transient exposure and no hepatotoxicity. In a mouse xenograft model, the platform successfully suppressed tumor growth via precision targeting. Collectively, these findings establish VLP-mediated CRISPR delivery as a versatile and safe integrated delivery platform, providing a comprehensive modality for both genome and epigenome editing in precision therapeutics.
Citation format
JU, Sungjin, et al. A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer. Molecular Therapy Nucleic Acids, 2026.